ARS Pharmaceuticals, Inc (SPRY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $391.06M
Last updated: Nov 17, 2026 at 11:06 AM ET
ARS Pharmaceuticals, Inc (SPRY) Earnings: Report Dates and Results
ARS Pharmaceuticals (SPRY) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, ARS Pharmaceuticals reported EPS of -$0.36, below the -$0.34 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SPRY has an expected report date of Mar 8, 2027.
SPRY Earnings Call
The latest SPRY earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 25 quarters below that had an estimate, SPRY beat 10, missed 14 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $37.71M, up 16.0% from $32.50M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.36 | -$0.34 | -$0.40 - -$0.29 | -5.88% | Miss | N/A | 3 | 1 up, 2 down | Nov 5, 2026 | $37.71M |
| Jun 30, 2026 | -$0.63 | -$0.55 | -$0.61 - -$0.36 | -14.55% | Miss | N/A | 3 | 1 up, 0 down | Aug 13, 2026 | $33.66M |
| Mar 31, 2026 | -$0.61 | -$0.53 | -$0.67 - -$0.47 | -15.09% | Miss | N/A | 4 | 0 up, 1 down | May 15, 2026 | $22.68M |
| Dec 31, 2025 | -$0.42 | -$0.42 | N/A | +1.08% | Beat | -182.4% | 4 | 1 up, 0 down | Mar 9, 2026 | $28.09M |
| Sep 30, 2025 | -$0.52 | -$0.49 | -$0.56 - -$0.46 | -6.12% | Miss | N/A | 5 | 1 up, 1 down | Nov 10, 2025 | $32.50M |
| Jun 30, 2025 | -$0.46 | -$0.51 | -$0.66 - -$0.42 | +9.80% | Beat | N/A | 4 | 0 up, 1 down | Aug 13, 2025 | $15.72M |
| Mar 31, 2025 | -$0.35 | -$0.36 | -$0.46 - -$0.31 | +2.78% | Beat | N/A | 4 | 0 up, 3 down | May 14, 2025 | $7.97M |
| Dec 31, 2024 | $0.51 | -$0.12 | -$0.31 - $0.28 | +534.04% | Beat | N/A | 4 | 2 up, 0 down | Mar 20, 2025 | $86.58M |
| Sep 30, 2024 | -$0.20 | -$0.14 | -$0.19 - -$0.06 | -42.86% | Miss | N/A | 4 | 0 up, 0 down | Nov 13, 2024 | $2.07M |
| Jun 30, 2024 | -$0.13 | -$0.11 | -$0.16 - -$0.09 | -18.18% | Miss | N/A | 3 | 0 up, 0 down | Aug 6, 2024 | $500000 |
| Mar 31, 2024 | -$0.11 | -$0.11 | -$0.14 - -$0.08 | 0.00% | In line | N/A | 2 | 0 up, 0 down | May 9, 2024 | N/A |
| Dec 31, 2023 | -$0.07 | -$0.14 | -$0.17 - -$0.11 | +50.00% | Beat | -109.1% | 3 | 0 up, 0 down | Mar 21, 2024 | N/A |
| Sep 30, 2023 | -$0.16 | -$0.18 | -$0.20 - -$0.16 | +11.11% | Beat | N/A | 3 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$0.18 | -$0.16 | -$0.20 - -$0.13 | -12.50% | Miss | N/A | 3 | 0 up, 0 down | Aug 10, 2023 | $10000 |
| Mar 31, 2023 | -$0.16 | -$0.15 | -$0.19 - -$0.13 | -6.67% | Miss | N/A | 3 | 0 up, 0 down | May 15, 2023 | $20000 |
| Dec 31, 2022 | $0.77 | -$0.13 | -$0.14 - -$0.12 | +692.31% | Beat | N/A | 2 | 0 up, 0 down | Mar 23, 2023 | N/A |
| Sep 30, 2022 | -$0.50 | -$0.35 | N/A | -42.86% | Miss | N/A | N/A | N/A | Nov 2, 2022 | $189000 |
| Jun 30, 2022 | -$0.55 | -$0.48 | N/A | -14.58% | Miss | N/A | N/A | N/A | Aug 11, 2022 | $464000 |
| Mar 31, 2022 | -$0.70 | -$0.54 | N/A | -29.63% | Miss | N/A | N/A | N/A | May 12, 2022 | $663000 |
| Dec 31, 2021 | -$0.67 | -$0.70 | N/A | +4.29% | Beat | N/A | N/A | N/A | Mar 31, 2022 | $5.51M |
| Sep 30, 2021 | -$0.65 | -$0.67 | N/A | +2.99% | Beat | N/A | N/A | N/A | Nov 10, 2021 | N/A |
| Jun 30, 2021 | -$0.70 | -$0.53 | N/A | -32.08% | Miss | N/A | N/A | N/A | Aug 12, 2021 | N/A |
| Mar 31, 2021 | -$0.54 | -$0.35 | N/A | -54.29% | Miss | N/A | N/A | N/A | May 13, 2021 | N/A |
| Dec 31, 2020 | -$1.37 | -$0.49 | N/A | -179.59% | Miss | N/A | N/A | N/A | Mar 29, 2021 | N/A |
| Sep 30, 2020 | -$0.70 | -$1.10 | N/A | +36.36% | Beat | N/A | N/A | N/A | Nov 10, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.75, after $0.07 the year before. It was -$2.07 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.75 | -2600.0% |
| Dec 31, 2024 | $0.07 | N/A |
| Dec 31, 2023 | -$0.57 | N/A |
| Dec 31, 2022 | -$0.98 | N/A |
| Dec 31, 2021 | -$2.56 | N/A |
| Dec 31, 2020 | -$2.07 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,300 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,346 | 8 | |
| 2026Q2 | Jun 30, 2026 | 3,472 | 8 | |
| 2026Q1 | Mar 31, 2026 | 5,025 | 9 | |
| 2025Q4 | Dec 31, 2025 | 4,440 | 9 | |
| 2025Q3 | Sep 30, 2025 | 6,146 | 11 | |
| 2025Q2 | Jun 30, 2025 | 4,324 | 9 | |
| 2025Q1 | Mar 31, 2025 | 4,265 | 11 | |
| 2024Q4 | Dec 31, 2024 | 8,864 | 11 |
2026Q3 Earnings Call
Opening remarks
Monique Allaire IR Representative Good afternoon, and thank you all for joining us. With me on the call today are President and CEO, Donn Casale; Chief Commercial Officer, Meg Smith; and our Chief Financial Officer, Kathy Scott. Earlier today, we issued a press release outlining ARS Pharma's commercial highlights and financial results for the third quarter of 2026. That press release can be found in the Investors and Media section of the company's website at ars-pharma.com. Before we begin, please note that today's remarks may contain forward-looking statements, and actual results may differ materially. Please refer to our press release and SEC filings for further risk disclosures. With that, I'll turn the call over to Donn.
Donn Casale President and CEO Thank you, Monique, and good afternoon, everyone. In August, I outlined a new strategic direction for ARS and laid out 3 corporate priorities to build a durable, profitable business. The first is disrupting the legacy epinephrine market with neffy, delivering steady market share gains through targeted provider commercial execution. The second is reaching cash flow breakeven by year-end 2027 based on greater financial discipline that will continue through 2027. The third is expanding our epinephrine delivery platform beyond anaphylaxis and unlocking value with the potential first on-demand treatment of breakthrough flares in chronic spontaneous urticaria, or CSU. I'm very proud of our progress last quarter and the team's execution against each of these priorities. In the third quarter, neffy continued to capture market share, delivering $33.4 million in U.S. net product revenue. Total U.S. market share surpassed 5%, up from 4% in the third quarter of 2025. This was driven by a 42% year-over-year increase in neffy end-user demand. We recorded more than 19,000 unique prescribers in the third quarter, up 49% year-over-year, for a total of nearly 45,000 prescribers since launch. The impact of our commercial execution is even more evident when you look at market share in field-targeted accounts, which represent about 44% of the total market opportunity. Field-targeted share increased from 6% in Q3 last year to 9% in Q3 this year, compared with 2% in non-targeted accounts. So where our field team engages, neffy wins. On our second priority, we have implemented strict financial discipline that we will maintain going forward. Operating expenses in Q3 were in line with the guidance we selected and set last year, reflecting our ongoing commitment to reducing SG&A spend. SG&A expenses in Q3 were down by more than 40% compared with the prior 2 quarters of this year. Based on our revised expense plan, we affirm that we are on track to achieve cash flow breakeven by year-end 2027.
Frequently Asked Questions About SPRY
When is ARS Pharmaceuticals's next earnings date?
ARS Pharmaceuticals's next earnings report is expected for Mar 8, 2027.
Did SPRY beat earnings estimates last quarter?
No. ARS Pharmaceuticals reported EPS of -$0.36 for the quarter ended Sep 30, 2026, below the -$0.34 estimate by 5.88%.
What EPS do analysts expect from SPRY next quarter?
The consensus EPS estimate for ARS Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.31 from 6 analysts, with estimates from -$0.41 to -$0.17.
How often does SPRY beat earnings estimates?
ARS Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +63.26%.
SPRY pages: Overview, Earnings, Forecast, Financials, Competitors